Navigation Links
Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
Date:4/8/2008

TAMPA, Fla., April 8, 2008 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today the presentation of data from two Phase 3 clinical trials of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, a topical steroid in the treatment of postoperative ocular inflammation. The results were given in a presentation by Michael Korenfeld, MD during the American Society of Cataract and Refractive Surgery Annual Symposium in Chicago, Illinois.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )

The two multi-center studies evaluated the safety and efficacy of Durezol(TM) 0.05% compared to placebo dosed twice a day (BID) and four times a day (QID) beginning 24 hours after ocular surgery. The studies included 438 subjects who presented with an anterior chamber cell grade 2 (greater than or equal to 10 cells) or higher the day after surgery. The clinically and statistically significant findings demonstrated that Durezol(TM), at both the BID and QID dosing regimens, was superior to placebo in achieving the primary endpoint of proportion of subjects with an anterior chamber cell grade of 0 (less than or equal to 1 cell) on Day 8, with 30% of subjects in the BID group reaching Grade 0 versus 9% in the placebo group. Of the subjects in the QID group, 35% reached Grade 0 on Day 8. In addition, Durezol(TM) maintained superiority over placebo through the treatment period (Day 15), with 56% in the BID group and 63% in the QID group reaching Grade 0 versus 16% in the placebo group.

Further data from the presentation demonstrated that both the BID and QID dosing regimens were superior to placebo with regard to change from baseline in anterior chamber cell count at Day 8. The mean reduction in cell count for subjects in both the BID and QID groups was 19 cells and the mean reduction in the placebo gr
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
2. Sirion Therapeutics Supports Ophthalmic Education
3. Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
4. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
5. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
6. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
7. Mercury Therapeutics Patents Filed
8. Cell Therapeutics, Inc. Announces Filing of Form 10-K
9. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
10. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
11. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014  Ardelyx, Inc. (NASDAQ: ARDX ... gastrointestinal and metabolic diseases, today announced that it ... Thursday, November 6, 2014. Following the announcement, the ... call and webcast at 4:30pm ET to review ... update. The live webcast can be ...
(Date:10/30/2014)... MA (PRWEB) October 30, 2014 ... and collaboration provider, offers Office 365 end users ... into a complete phone system by adding voice ... 365 (O365) includes Lync Online, a communication tool ... Lync calls. With hosted voice, O365 becomes a ...
(Date:10/30/2014)... 30, 2014 Whitehouse Laboratories has formally ... Stability Testing and Package Test Capacity. Responding to growing ... a dramatic increase in environmental chamber storage space that ... and aging samples to be securely held on site ... capital expenditure has already taken place with the recent ...
(Date:10/30/2014)... A new report, commissioned by BioCrossroads and conducted by ... at Indiana,s capital market and ... time frames: 1993 to 2002 and 2003 to 2013.  ... investment growth.  The Life Science Innovation Capital in ... innovation dollars as well as an increase in life ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5
... RIVER, N.Y., June 20, 2011 ... provider of software and services for health and ... 4.2 electronic health record (EHR) software for behavioral ... ARRA Ambulatory Certification. (Logo: http://photos.prnewswire.com/prnh/20110620/NY22778LOGO) ...
... VICTORIA, Australia, June 20, 2011 Genetic Technologies Limited ... North American division, Phenogen Sciences Inc., has launched the ... risk.   Phenogen Sciences will target its ... US metro-markets.  The company has deployed its sales force ...
... ,Graphene, a one-atom-thick layer of graphitic carbon, has the ... But its unique properties, and the shrinking scale of ... produce on a large scale. In ... had overcome some of these difficulties and were able ...
Cached Biology Technology:CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 2CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 3CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 4Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 2Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 4UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits 2
(Date:10/29/2014)... been blamed for increasing the risk of a ... history of schizophrenia, are widely accepted. Others, such ... parasite transmitted by soil, undercooked meat and cat ... new study by Gary Smith, professor of population ... School of Veterinary Medicine, used epidemiological modeling methods ...
(Date:10/29/2014)... ceremony held in New York City on September 19, ... American Cancer Society Professor of Genome Sciences and Medicine ... Honorary Doctor of Philosophy of Tel Aviv University, was ... Science. , In addition to her honorary degree from ... the TAU School of Medicine, and for the past ...
(Date:10/29/2014)... the Barcode of Life Data Systems (BOLD). ... Data Journal (BDJ) used specimen records downloaded ... a human-readable text developed in manuscript within the ... study the species distributions of ten Nearctic species of ... originally designed to support the generation and application of ...
Breaking Biology News(10 mins):Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2
... great hope for the treatment of some devastating diseases, but ... and healthy for transplantation in patients has been an ongoing ... to keep large quantities of these cells alive, a finding ... for therapeutic use at lower cost. , These findings ...
... Mayo Clinic-led research collaboration has discovered that the protein ... can begin. Once amplified, even low-level damage signals become ... while the injury is most tractable to repair. ... until this finding, which appears in the January 20 ...
... like pandas, gorillas and tigers helps reduce poverty and ... new World Wildlife Fund report. Now as the eighth ... Diversity opens today in Curitiba, Brazil, WWF urges the ... into efforts to alleviate poverty. , "Now's the ...
Cached Biology News:UCI researchers discover key factor for survival of human embryonic stem cells 2Mayo Clinic collaboration discovers protein amplifies DNA injury signals 2Mayo Clinic collaboration discovers protein amplifies DNA injury signals 3Protecting endangered species helps reduce poverty 2
... Highly nutritious peptone, ... the production of bacterial ... cultivation of bacteria with ... Corynbacterium, Haemophilus, Neisseria, Pasteurella, ...
... RPMI 1640 with 2 mM L-glutamine and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... StabilCoat Plus Microsphere/Microarray Stabilizer is an ... protein and other non-toxic chemicals in a ... 7.4. This product contains a ... as a preservative. StabilCoat Plus Stabilizer ...
... ABgene's Protein Purification Plates are designed for ... gels. The 96-well plates feature two 0.25mm ... of each well. The wells remain liquid-tight ... buffer, during which time the protein diffuses ...
Biology Products: